Exelixis (EXEL) Other Non-Current Assets (2010 - 2022)
Exelixis (EXEL) recorded quarterly Other Non-Current Assets of $280.0 million in Q3 2022, little changed quarter-over-quarter from $279.7 million in Q3 2022, and up 107.91% on a YoY basis from $134.7 million in Q3 2021.
Exelixis (EXEL) Other Non-Current Assets (2010 - 2022) Analysis & Trends
Exelixis' Other Non-Current Assets history runs 13 years deep, the most recent figure standing at $280.0 million for Q3 2022.
- In Q3 2022, Other Non-Current Assets rose 107.91% year-over-year to $280.0 million; the TTM figure through Sep 2022 stood at $280.0 million (up 107.91% YoY), while the FY2021 annual figure was $131.0 million, up 78.46% from the prior year.
- Other Non-Current Assets was $280.0 million for Q3 2022 at Exelixis, roughly flat from $279.7 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $280.0 million in Q3 2022 to a low of $1.0 million in Q3 2019.
- Historically, Other Non-Current Assets has averaged $81.7 million across 5 years, with a median of $60.5 million in 2020.
- The sharpest annual moves came in 2019 and 2020: Other Non-Current Assets declined 26.67% in 2019, then soared 6840.9% in 2020.
- A 5-year view of Other Non-Current Assets shows it stood at $8.3 million in 2018, then slumped by 87.94% to $1.0 million in 2019, then jumped by 6840.9% to $69.4 million in 2020, then surged by 88.74% to $131.0 million in 2021, then jumped by 113.74% to $280.0 million in 2022.
- The last three Other Non-Current Assets figures came in at $280.0 million (Q3 2022), $279.7 million (Q3 2022), and $139.0 million (Q2 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 60,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Exelixis | 13.37 Bn | 12.59 Bn | 590.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 280.01 Mn |
| Jul 1, 2022 | 279.71 Mn |
| Apr 1, 2022 | 138.99 Mn |
| Dec 31, 2021 | 131.00 Mn |
| Oct 1, 2021 | 134.68 Mn |
| Jul 2, 2021 | 134.93 Mn |
| Apr 2, 2021 | 124.68 Mn |
| Jan 1, 2021 | 73.41 Mn |
| Oct 2, 2020 | 69.41 Mn |
| Jul 3, 2020 | 60.50 Mn |
| Apr 3, 2020 | 57.31 Mn |
| Jan 3, 2020 | 53.15 Mn |
| Sep 27, 2019 | 1.00 Mn |
| Jun 28, 2019 | 1.10 Mn |
| Mar 29, 2019 | 1.10 Mn |
| Dec 28, 2018 | 8.29 Mn |
| Sep 28, 2018 | 1.10 Mn |
| Jun 29, 2018 | 1.10 Mn |
| Mar 30, 2018 | 1.50 Mn |
| Dec 29, 2017 | 4.65 Mn |